Navigation Links
RiOs 3 Reverse Osmosis System

ProductsRiOs 3 Reverse Osmosis System
Company Millipore
Item RiOs 3 Reverse Osmosis System
Features Inquire
Description RiOs systems produce Type III, laboratory-grade pure water at a constant flow rate. Systems are fed directly with potable tap water and combine complementary purification technologies in a compact system design that is easy to operate, reliable, and allows total control over the water produced at a low operating cost.

Applications

  • Glassware rinsing
  • Feedwater for humidifiers, autoclaves, washing machines
  • Feedwater for Milli-Q ultrapure water systems
Features
  • Easy-to-install (plug and use concept) prefiltration pack unit includes three types of purification media
  • Self-maintenance of the reverse osmosis membrane
  • Advanced reverse osmosis technology with high recovery loop reduces water consumption by more than 50 %
  • Constant product flow rate
  • Optional UV lamp for optimum water quality for applications sensitive to bacteria
  • All system functions are accessible from a user-friendly keypad and displayed on backlit screen
  • Optional Explore Data software
Info Millipore
Customer Service: (978) 715-4321
Web site: http://www.millipore.com/

Related medicine products :

1. Graham Field 10 Reversed Snellen Eye Chart
2. Reverse phaco chopper
3. Cobb Curettes, Reverse Angled, 11
4. Reverse Double Barreled Irrigation/Aspiration Set
5. Irrigating Cystotome - Reverse
6. Blunt Tip Cystotome - Reverse
7. RiOs 5 Reverse Osmosis System
8. RiOs 8 Reverse Osmosis System
9. RiOs 16 Reverse Osmosis System
10. arium 613 Reverse Osmosis System
11. arium Water Tower Integrated Reverse Osmosis and Ultrapure Water System
Breaking Medicine Technology:Hand Surgeons Take Ethics into Their Own Hands 2Hand Surgeons Take Ethics into Their Own Hands 3Hand Surgeons Take Ethics into Their Own Hands 4Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug 2Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug 3FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 2FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 3FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 4National Patient Safety Foundation Supports Mandatory Flu Vaccinations for Healthcare Workers 61647 1National Patient Safety Foundation Supports Mandatory Flu Vaccinations for Healthcare Workers 61647 2National Patient Safety Foundation Supports Mandatory Flu Vaccinations for Healthcare Workers 61647 3Reportlinker Adds Biotechnology Reagents A Global Market Perspective 14905 1Reportlinker Adds Biotechnology Reagents A Global Market Perspective 14905 2Reportlinker Adds Biotechnology Reagents A Global Market Perspective 14905 3Reportlinker Adds Biotechnology Reagents A Global Market Perspective 14905 4Reportlinker Adds Biotechnology Reagents A Global Market Perspective 14905 5Reportlinker Adds Biotechnology Reagents A Global Market Perspective 14905 6Reportlinker Adds Biotechnology Reagents A Global Market Perspective 14905 7Reportlinker Adds Biotechnology Reagents A Global Market Perspective 14905 8Improving Quality Cost Effectiveness and Time Savings in Preclinical Inhalable Formulation Development 6386 1Improving Quality Cost Effectiveness and Time Savings in Preclinical Inhalable Formulation Development 6386 2